PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
3.570
-0.010 (-0.28%)
At close: Jun 27, 2025, 4:00 PM
3.600
+0.030 (0.84%)
After-hours: Jun 27, 2025, 7:44 PM EDT

Company Description

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.

Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.

It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer.

The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors.

PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PolyPid Ltd.
PolyPid logo
Country Israel
Founded 2008
IPO Date Jun 26, 2020
Industry Biotechnology
Sector Healthcare
Employees 60
CEO Dikla Czaczkes Akselbrad

Contact Details

Address:
18 Hasivim Street
Petah Tikva, 4959376
Israel
Phone 972 7 4719 5700
Website polypid.com

Stock Details

Ticker Symbol PYPD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001611842
CUSIP Number M8001Q118
ISIN Number IL0011326795
SIC Code 3841

Key Executives

Name Position
Dalit Hazan Deputy Chief Executive Officer and Executive Vice President of Research & Development, Clinical and Regulatory Affairs
Dikla Czaczkes Akselbrad Chief Executive Officer and Director
Jonny Missulawin Chief Financial Officer
Ori Warshavsky Chief Operating Officer - US
Maria Rubin Executive Vice President of Operations
Tal Vilnai General Counsel and Corporate Secretary
Rivi Lev-ari Vice President of Human Resource
Dr. Jean-Marc Hagai Pharm.D. Chief Commercial Officer

Latest SEC Filings

Date Type Title
Jun 25, 2025 6-K Report of foreign issuer
Jun 23, 2025 D Notice of Exempt Offering of Securities
Jun 17, 2025 6-K Report of foreign issuer
Jun 9, 2025 6-K Report of foreign issuer
May 30, 2025 6-K Report of foreign issuer
May 28, 2025 SCHEDULE 13G/A Filing
May 21, 2025 6-K Report of foreign issuer
May 15, 2025 SCHEDULE 13G/A Filing
May 14, 2025 6-K Report of foreign issuer
Apr 3, 2025 SCHEDULE 13G/A Filing